- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05256225
Test dell'aggiunta di trastuzumab o trastuzumab/pertuzumab alla consueta chemioterapia per carcinoma sieroso endometriale HER2 positivo o carcinosarcoma
Uno studio di fase II/III su paclitaxel/carboplatino da solo o in combinazione con trastuzumab e ialuronidasi-Oysk (HERCEPTIN HYLECTA) o pertuzumab, trastuzumab e ialuronidasi-Zzxf (PHESGO) nel carcinoma o nel carcinoma sieroso endometriale HER2 positivo, stadio I-IV
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Panoramica dello studio
Stato
Condizioni
- Carcinoma endometriale
- Adenocarcinoma endometriale a cellule chiare
- Carcinoma dedifferenziato dell'endometrio
- Adenocarcinoma endometrioide endometriale
- Adenocarcinoma endometriale a cellule miste
- Adenocarcinoma sieroso endometriale
- Carcinoma indifferenziato dell'endometrio
- Tumore Maligno Misto Mesodermico (Mulleriano) del Corpo Uterino
Intervento / Trattamento
- Droga: Carboplatin
- Droga: Paclitaxel
- Procedura: Computed Tomography
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Procedura: Biospecimen Collection
- Radiazione: High-Dose-Rate Vaginal Cuff Brachytherapy
- Altro: Survey Administration
- Droga: Trastuzumab/Hyaluronidase-oysk
- Droga: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.
II. To evaluate the overall response rate (ORR) in patients with measurable disease.
III. To evaluate the duration of objective response in patients with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0 for each treatment arm.
V. To compare quality of life (QOL), as measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En-TOI), in the experimental versus control arms.
VI. To compare patient-reported treatment-associated symptoms (diarrhea and rash) as measured with the Patient Reported Outcomes (PRO) - CTCAE, patient-reported fatigue as measured with the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue short form, and worry concerning side effects of treatment as measured by the item 'bothered by side effect', in the FACT-En TOI, respectively, in the experimental and control arms.
VII. To assess the correlation of HER2 immunohistochemistry (IHC) expression and in situ hybridization (ISH) amplification with clinical outcome and response to HER2 targeted therapies.
EXPLORATORY OBJECTIVE:
I. To explore time to sustained deterioration in quality of life, as measured by a drop in the FACT-En-TOI by 6 or more points lasting for more than one PRO time point, in the experimental and control arms.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
ARM II: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.
ARM III: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.
MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment.
Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and computed tomography (CT) throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Seoul, Corea del Sud, 06273
- Gangnam Severance Hospital
-
-
Daegu
-
Dalseo-gu, Daegu, Corea del Sud, 42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, Corea del Sud, 51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam, Kyeonggi-do, Corea del Sud, 463-707
- Seoul National University Bundang Hospital
-
-
-
-
-
San Juan, Porto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Stati Uniti, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Stati Uniti, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, Stati Uniti, 94520
- John Muir Medical Center-Concord
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Huntington Beach, California, Stati Uniti, 92648
- City of Hope Seacliff
-
Irvine, California, Stati Uniti, 92618
- Kaiser Permanente-Irvine
-
Irvine, California, Stati Uniti, 92618
- City of Hope at Irvine Lennar
-
Irvine, California, Stati Uniti, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Long Beach, California, Stati Uniti, 90813
- City of Hope at Long Beach Elm
-
Los Angeles, California, Stati Uniti, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Modesto, California, Stati Uniti, 95355
- Memorial Medical Center
-
Mountain View, California, Stati Uniti, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Orange, California, Stati Uniti, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Stati Uniti, 92868
- Saint Joseph Hospital - Orange
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
Panorama City, California, Stati Uniti, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, Stati Uniti, 92505
- Kaiser Permanente-Riverside
-
Roseville, California, Stati Uniti, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, Stati Uniti, 94115
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Stati Uniti, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Sunnyvale, California, Stati Uniti, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland, California, Stati Uniti, 91786
- City of Hope Upland
-
Walnut Creek, California, Stati Uniti, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- UCHealth University of Colorado Hospital
-
Denver, Colorado, Stati Uniti, 80206
- UCHealth - Cherry Creek
-
Denver, Colorado, Stati Uniti, 80210
- AdventHealth Porter
-
Grand Junction, Colorado, Stati Uniti, 81505
- Grand Valley Oncology
-
Greeley, Colorado, Stati Uniti, 80631
- Banner North Colorado Medical Center
-
Highlands Ranch, Colorado, Stati Uniti, 80129
- UCHealth Highlands Ranch Hospital
-
Loveland, Colorado, Stati Uniti, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury, Connecticut, Stati Uniti, 06810
- Danbury Hospital
-
Derby, Connecticut, Stati Uniti, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Stati Uniti, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Stati Uniti, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Stati Uniti, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Stati Uniti, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Stati Uniti, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
North Haven, Connecticut, Stati Uniti, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk, Connecticut, Stati Uniti, 06856
- Norwalk Hospital
-
Stamford, Connecticut, Stati Uniti, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Stati Uniti, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Stati Uniti, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Stati Uniti, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Stati Uniti, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Stati Uniti, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stati Uniti, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20037
- George Washington University Medical Center
-
Washington D.C., District of Columbia, Stati Uniti, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Broward Health Medical Center
-
Jupiter, Florida, Stati Uniti, 33458
- Jupiter Medical Center
-
N. Venice, Florida, Stati Uniti, 34275
- Sarasota Memorial Hospital-Venice
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
Sarasota, Florida, Stati Uniti, 34239
- Sarasota Memorial Hospital
-
Sarasota, Florida, Stati Uniti, 34239
- Florida Cancer Specialists - Sarasota Downtown
-
Sarasota, Florida, Stati Uniti, 34239
- FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery
-
Venice, Florida, Stati Uniti, 34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Stati Uniti, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Stati Uniti, 30303
- Grady Health System
-
Atlanta, Georgia, Stati Uniti, 30309
- Piedmont Hospital
-
Augusta, Georgia, Stati Uniti, 30912
- Augusta University Medical Center
-
Decatur, Georgia, Stati Uniti, 30033
- Emory Decatur Hospital
-
Savannah, Georgia, Stati Uniti, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Arlington Heights, Illinois, Stati Uniti, 60005
- Northwest Community Hospital
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Stati Uniti, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Evanston, Illinois, Stati Uniti, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview, Illinois, Stati Uniti, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stati Uniti, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Stati Uniti, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale, Illinois, Stati Uniti, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Lake Forest, Illinois, Stati Uniti, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stati Uniti, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Normal, Illinois, Stati Uniti, 61761
- Carle Cancer Institute Normal
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Stati Uniti, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Stati Uniti, 60462
- Northwestern Medicine Orland Park
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville, Illinois, Stati Uniti, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Carmel, Indiana, Stati Uniti, 46032
- IU Health North Hospital
-
Crown Point, Indiana, Stati Uniti, 46307
- UChicago Medicine Northwest Indiana
-
Crown Point, Indiana, Stati Uniti, 46307
- Northwest Cancer Center - Crown Point
-
Dyer, Indiana, Stati Uniti, 46311
- Northwest Oncology LLC
-
Goshen, Indiana, Stati Uniti, 46526
- Goshen Center for Cancer Care
-
Hobart, Indiana, Stati Uniti, 46342
- Northwest Cancer Center - Hobart
-
Hobart, Indiana, Stati Uniti, 46342
- Saint Mary Medical Center
-
Indianapolis, Indiana, Stati Uniti, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Stati Uniti, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis, Indiana, Stati Uniti, 46312
- Saint Catherine Hospital
-
Lafayette, Indiana, Stati Uniti, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Mooresville, Indiana, Stati Uniti, 46158
- Franciscan Health Mooresville
-
Munster, Indiana, Stati Uniti, 46321
- The Community Hospital
-
Munster, Indiana, Stati Uniti, 46321
- Women's Diagnostic Center - Munster
-
South Bend, Indiana, Stati Uniti, 46601
- Memorial Hospital of South Bend
-
Valparaiso, Indiana, Stati Uniti, 46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Boone, Iowa, Stati Uniti, 50036
- McFarland Clinic - Boone
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Fort Dodge, Iowa, Stati Uniti, 50501
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Stati Uniti, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Shawnee Mission, Kansas, Stati Uniti, 66204
- AdventHealth Shawnee Mission
-
-
Kentucky
-
Edgewood, Kentucky, Stati Uniti, 41017
- Saint Elizabeth Healthcare Edgewood
-
Lexington, Kentucky, Stati Uniti, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Stati Uniti, 40207
- Baptist Health Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Stati Uniti, 70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Stati Uniti, 70433
- Ochsner Hematology Oncology North Shore - Covington (West Region)
-
Marrero, Louisiana, Stati Uniti, 70072
- West Jefferson Medical Center
-
Metairie, Louisiana, Stati Uniti, 70006
- East Jefferson General Hospital
-
Metairie, Louisiana, Stati Uniti, 70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Stati Uniti, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Stati Uniti, 70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta, Maine, Stati Uniti, 04330
- Harold Alfond Center for Cancer Care
-
Scarborough, Maine, Stati Uniti, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stati Uniti, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Stati Uniti, 21204
- Greater Baltimore Medical Center
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Walter Reed National Military Medical Center
-
Westminster, Maryland, Stati Uniti, 21157
- William E Kahlert Regional Cancer Center/Sinai Hospital
-
-
Massachusetts
-
Springfield, Massachusetts, Stati Uniti, 01199
- Baystate Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Stati Uniti, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Chelsea, Michigan, Stati Uniti, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Weisberg Cancer Treatment Center
-
Farmington Hills, Michigan, Stati Uniti, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Stati Uniti, 48503
- Hurley Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stati Uniti, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Stati Uniti, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49009
- Beacon Kalamazoo Cancer Center
-
Lansing, Michigan, Stati Uniti, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stati Uniti, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Muskegon, Michigan, Stati Uniti, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stati Uniti, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stati Uniti, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Pontiac, Michigan, Stati Uniti, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Reed City, Michigan, Stati Uniti, 49677
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Stati Uniti, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Stati Uniti, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Tawas City, Michigan, Stati Uniti, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Stati Uniti, 49684
- Munson Medical Center
-
Troy, Michigan, Stati Uniti, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Stati Uniti, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Stati Uniti, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Minnesota Oncology - Edina
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Marshall, Minnesota, Stati Uniti, 56258
- Avera Cancer Institute at Marshall
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota/Masonic Cancer Center
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
Woodbury, Minnesota, Stati Uniti, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla, Missouri, Stati Uniti, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Stati Uniti, 65807
- CoxHealth South Hospital
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stati Uniti, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Stati Uniti, 59102
- Saint Vincent Frontier Cancer Center
-
Billings, Montana, Stati Uniti, 59106
- Intermountain Health West End Clinic
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stati Uniti, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stati Uniti, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stati Uniti, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stati Uniti, 89106
- Women's Cancer Center of Nevada
-
Las Vegas, Nevada, Stati Uniti, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
Lakewood, New Jersey, Stati Uniti, 08701
- Monmouth Medical Center Southern Campus
-
Livingston, New Jersey, Stati Uniti, 07039
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, Stati Uniti, 07740
- Monmouth Medical Center
-
Middletown, New Jersey, Stati Uniti, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stati Uniti, 07645
- Memorial Sloan Kettering Bergen
-
Moorestown, New Jersey, Stati Uniti, 08057
- Virtua Samson Cancer Center
-
Neptune City, New Jersey, Stati Uniti, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, Stati Uniti, 07101
- Rutgers New Jersey Medical School
-
Red Bank, New Jersey, Stati Uniti, 07701
- Riverview Medical Center/Booker Cancer Center
-
Sewell, New Jersey, Stati Uniti, 08080
- Sidney Kimmel Cancer Center Washington Township
-
Somerville, New Jersey, Stati Uniti, 08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River, New Jersey, Stati Uniti, 08755
- Community Medical Center
-
Voorhees Township, New Jersey, Stati Uniti, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Stati Uniti, 87110
- Presbyterian Kaseman Hospital
-
Rio Rancho, New Mexico, Stati Uniti, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Women's Cancer Care Associates LLC
-
Commack, New York, Stati Uniti, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering Westchester
-
Mineola, New York, Stati Uniti, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10029
- Mount Sinai Hospital
-
New York, New York, Stati Uniti, 10011
- Mount Sinai Chelsea
-
New York, New York, Stati Uniti, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Weiler Hospital
-
Uniondale, New York, Stati Uniti, 11553
- Memorial Sloan Kettering Nassau
-
Webster, New York, Stati Uniti, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Cary, North Carolina, Stati Uniti, 27518
- Duke Cancer Center Cary
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Stati Uniti, 27834
- ECU Health Medical Center
-
High Point, North Carolina, Stati Uniti, 27262
- Hayworth Cancer Center
-
Raleigh, North Carolina, Stati Uniti, 27607
- Duke Women's Cancer Care Raleigh
-
Wilmington, North Carolina, Stati Uniti, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Beachwood, Ohio, Stati Uniti, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Stati Uniti, 45714
- Strecker Cancer Center-Belpre
-
Canton, Ohio, Stati Uniti, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Stati Uniti, 45459
- Miami Valley Hospital South
-
Chardon, Ohio, Stati Uniti, 44024
- Geauga Hospital
-
Chillicothe, Ohio, Stati Uniti, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Stati Uniti, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stati Uniti, 44109
- MetroHealth Medical Center
-
Columbus, Ohio, Stati Uniti, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Stati Uniti, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Stati Uniti, 43213
- Mount Carmel East Hospital
-
Dayton, Ohio, Stati Uniti, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Miami Valley Hospital North
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Stati Uniti, 45331
- Miami Valley Cancer Care and Infusion
-
Grove City, Ohio, Stati Uniti, 43123
- Mount Carmel Grove City Hospital
-
Lancaster, Ohio, Stati Uniti, 43130
- Fairfield Medical Center
-
Lima, Ohio, Stati Uniti, 45801
- Saint Rita's Medical Center
-
Marietta, Ohio, Stati Uniti, 45750
- Marietta Memorial Hospital
-
Marysville, Ohio, Stati Uniti, 43040
- Memorial Hospital
-
Mentor, Ohio, Stati Uniti, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Mount Vernon, Ohio, Stati Uniti, 43050
- Knox Community Hospital
-
Newark, Ohio, Stati Uniti, 43055
- Licking Memorial Hospital
-
Parma, Ohio, Stati Uniti, 44129
- University Hospitals Parma Medical Center
-
Perrysburg, Ohio, Stati Uniti, 43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth, Ohio, Stati Uniti, 45662
- Southern Ohio Medical Center
-
Springfield, Ohio, Stati Uniti, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Stati Uniti, 45504
- Springfield Regional Medical Center
-
Sylvania, Ohio, Stati Uniti, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Stati Uniti, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Stati Uniti, 43608
- Mercy Health - Saint Vincent Hospital
-
Troy, Ohio, Stati Uniti, 45373
- Upper Valley Medical Center
-
Westerville, Ohio, Stati Uniti, 43081
- Saint Ann's Hospital
-
Westlake, Ohio, Stati Uniti, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville, Ohio, Stati Uniti, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Mercy Hospital Oklahoma City
-
Tulsa, Oklahoma, Stati Uniti, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Clackamas, Oregon, Stati Uniti, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Stati Uniti, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
Tualatin, Oregon, Stati Uniti, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Stati Uniti, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Stati Uniti, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr, Pennsylvania, Stati Uniti, 19010
- Bryn Mawr Hospital
-
East Stroudsburg, Pennsylvania, Stati Uniti, 18301
- Pocono Medical Center
-
Easton, Pennsylvania, Stati Uniti, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, Stati Uniti, 16544
- Saint Vincent Hospital
-
Hazleton, Pennsylvania, Stati Uniti, 18201
- Lehigh Valley Hospital-Hazleton
-
Jefferson Hills, Pennsylvania, Stati Uniti, 15025
- Jefferson Hospital
-
Media, Pennsylvania, Stati Uniti, 19063
- Riddle Memorial Hospital
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- Forbes Hospital
-
Paoli, Pennsylvania, Stati Uniti, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Pennsylvania Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- West Penn Hospital
-
Quakertown, Pennsylvania, Stati Uniti, 18951
- Saint Luke's Hospital - Upper Bucks Campus
-
West Chester, Pennsylvania, Stati Uniti, 19380
- Chester County Hospital
-
Wexford, Pennsylvania, Stati Uniti, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Asplundh Cancer Pavilion
-
Wynnewood, Pennsylvania, Stati Uniti, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02905
- Women and Infants Hospital
-
Westerly, Rhode Island, Stati Uniti, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Carolina
-
Bluffton, South Carolina, Stati Uniti, 29910
- Saint Joseph's/Candler - Bluffton Campus
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Aberdeen, South Dakota, Stati Uniti, 57401
- Avera Cancer Institute-Aberdeen
-
Rapid City, South Dakota, Stati Uniti, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- The West Clinic - Wolf River
-
-
Texas
-
Austin, Texas, Stati Uniti, 78712
- University of Texas at Austin
-
Austin, Texas, Stati Uniti, 78701
- Dell Seton Medical Center at The University of Texas
-
Dallas, Texas, Stati Uniti, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Fort Worth, Texas, Stati Uniti, 76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Fort Worth, Texas, Stati Uniti, 76104
- Tarrant County Hospital District/JPS Health Network
-
Houston, Texas, Stati Uniti, 77030
- Houston Methodist Hospital
-
Houston, Texas, Stati Uniti, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, Stati Uniti, 77070
- Methodist Willowbrook Hospital
-
Houston, Texas, Stati Uniti, 77094
- Houston Methodist West Hospital
-
Nassau Bay, Texas, Stati Uniti, 77058
- Houston Methodist Saint John Hospital
-
Richardson, Texas, Stati Uniti, 75080
- UT Southwestern Clinical Center at Richardson/Plano
-
Sugar Land, Texas, Stati Uniti, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Stati Uniti, 77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Huntsman Cancer Institute/University of Utah
-
South Jordan, Utah, Stati Uniti, 84009
- South Jordan Health Center
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23229
- Henrico Doctor's Hospital
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Stati Uniti, 24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Edmonds, Washington, Stati Uniti, 98026
- Swedish Cancer Institute-Edmonds
-
Seattle, Washington, Stati Uniti, 98122
- Swedish Medical Center-First Hill
-
Vancouver, Washington, Stati Uniti, 98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Medical Center-EC Cancer Center
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Stati Uniti, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Stati Uniti, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Stati Uniti, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Stati Uniti, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Sheboygan Physicians Group
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay, Wisconsin, Stati Uniti, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha, Wisconsin, Stati Uniti, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible:
-
Serous
-
Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated)
-
Carcinosarcoma
- NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible
-
-
Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required
-
Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration
-
Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded
-
All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines. IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following:
- 3+ immunohistochemistry (IHC),
- 2+ IHC with positive in situ hybridization (ISH) Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial.
Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted.
Sites must submit all results available (IHC, ISH, and NGS)
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Age >= 18
-
Platelets >= 100,000/mcl (within 14 days prior to registration)
-
Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration)
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) >= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR) (within 14 days prior to registration)
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
-
Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration
- Have a congenital or acquired condition that prevents childbearing
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria:
-
Prior Therapy:
-
Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma
-
Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy
- NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration
-
-
Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration
-
Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration
-
Significant cardiovascular disease including:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg despite antihypertensive medications
- Myocardial infarction or unstable angina within 6 months prior to registration
- New York Heart Association functional classification II, III or IV
- Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate
-
Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)
-
Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements
-
Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration
-
Women who are unwilling to discontinue nursing
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm I (paclitaxel, carboplatin)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo blood and urine sample collection
Altri nomi:
Undergo vaginal brachytherapy
Altri nomi:
|
|
Sperimentale: Arm II (paclitaxel, carboplatin, Herceptin Hylecta)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo blood and urine sample collection
Altri nomi:
Undergo vaginal brachytherapy
Altri nomi:
Ancillary studies Given SC
Altri nomi:
|
|
Sperimentale: Arm III (paclitaxel, carboplatin, Phesgo)
See Detailed Description. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo blood and urine sample collection
Altri nomi:
Undergo vaginal brachytherapy
Altri nomi:
Ancillary studies Given SC
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression free survival
Lasso di tempo: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization
|
At the end of Phase 2 analysis, if both experimental arms demonstrate superiority to the reference, the experimental arms will be compared to each other. |
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization
|
|
Overall survival
Lasso di tempo: From study entry to time of death or the date of last contact, assessed up to 5 years from randomization
|
If both experimental arms demonstrate superiority to the reference arm, the experimental arms will be compared to each other. |
From study entry to time of death or the date of last contact, assessed up to 5 years from randomization
|
|
Incidence of dose limiting toxicities
Lasso di tempo: Up to end of cycle 3 (week 12)
|
A dose limiting toxicity is any treatment-related adverse event requiring permanent discontinuation of the experimental therapy prior to the completion of treatment cycle 3. |
Up to end of cycle 3 (week 12)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective response rate (ORR)
Lasso di tempo: Within 12 months of initiating maintenance therapy
|
Defined as the binomial proportion of evaluable patients with a best overall response of complete response or partial response (by Response Evaluation Criteria in Solid Tumors 1.1) within 12 months of initiating maintenance therapy. Responses reported by the treating physician will be used for these analyses. The ORR estimates by treatment arm will be supported by their 2-sided, 95% Wilson-Score confidence intervals (Wilson, 1927; Agresti, 1998). The relative odds of response in each experimental group (versus [vs] the reference group) will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and covariate adjustments for the stratification factors reported at baseline. |
Within 12 months of initiating maintenance therapy
|
|
Duration of objective response
Lasso di tempo: From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization
|
Treatment group differences in response duration will be graphed using Kaplan-Meier methods and compared using logrank tests, stratified by the minimization factors defined at randomization. The relative hazards of progression or death in each experimental group (vs the reference group) will be estimated using a multivariable proportional hazards regression model specified with main effects for the treatment indicators and covariate adjustments for the stratification factors reported at baseline. |
From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization
|
|
Incidence of adverse events (AEs)
Lasso di tempo: Up to 5 years from randomization
|
The nature, frequency, and degree of toxicity will be tabulated at the System Organ Class and AE-specific term levels using Common Terminology Criteria version 5.0. Each patient will be represented according to the maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment. |
Up to 5 years from randomization
|
|
HER2 expression
Lasso di tempo: Up to 5 years from randomization
|
Correlation of HER2 immunohistochemistry expression and in situ hybridization amplification with clinical outcome and response to HER2 targeted therapies will be explored. |
Up to 5 years from randomization
|
|
Quality of life (QoL)
Lasso di tempo: Up to 5 years from randomization
|
Measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En TOI). |
Up to 5 years from randomization
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
QoL deterioration
Lasso di tempo: Baseline up to 5 years
|
The deterioration in QoL will be measured by a drop of >= 6 points in the FACT-En TOI score from baseline and lasting for more than one patient reported outcome time point in experimental and control arms. |
Baseline up to 5 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Britt K Erickson, NRG Oncology
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Neoplasie urogenitali
- Neoplasie per sede
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie genitali, femmina
- Neoplasie uterine
- Neoplasie
- Neoplasie endometriali
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Glicoside idrolasi
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Polisaccaride-Laryases
- Liasi di ossigeno carbonio
- Lyasi
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Economia e organizzazioni sanitarie
- Economia
- Trastuzumab
- Carboplatino
- Paclitaxel
- Ialuronoglucosaminidasi
- Gestione dei campioni
- pertuzumab
- Tasse
Altri numeri di identificazione dello studio
- NCI-2022-01540
- U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2022-01540 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- NRG-GY026 (Altro identificatore: CTEP)
- NRG-GY026 (Altro identificatore: NRG Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .